A K Prabhakar

Buy NMDC To Achieve Target Of Rs 291

Buy NMDC To Achieve Target Of Rs 291Technical analyst AK Prabhakar of Anand Rathi Securities has maintained 'buy' rating on NMDC Limited stock to attain a target of Rs 291.

The stock can be purchased with a stop loss of Rs 266.

Today, the stock of the company opened at Rs 274 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 374.80 and a low of Rs 239.95 on BSE.

Current EPS & P/E ratio stood at 13.79 and 19.87 respectively.

Sell SBI With Target Of Rs 2400

Sell SBI With Target Of Rs 2400Technical analyst A. K Prabhakar of Anand Rathi has maintained 'sell' rating on State Bank of India Limited stock with a target of Rs 2400.

Mr. Prabhakar added that it is better to sell SBI stock at this time as there are chances of downfall in the coming days.

The interested investors can enter the stock again on declines to reap gains in the medium and long term, he added.

Today, the stock of the bank opened at Rs 2783.50 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 3515 and a low of Rs 1890 on BSE.

Long Term Buy Call For Mahindra & Mahindra

Mahindra & MahindraTechnical analyst A. K Prabhakar of Anand Rathi has maintained 'hold' rating on Mahindra & Mahindra Limited to achieve long term target.

The analyst said that the stock can be purchased with a target of Rs 1200.

Mr. Prabhakar said that the said target can be attained in a period of 12 months.

Today, the stock of the company opened at Rs 755 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 826.40 and a low of Rs 475.55 on BSE.

Current EPS & P/E ratio stood at 39.73 and 19.10 respectively.

Hold Glenmark For Long Term

Hold Glenmark For Long TermStock market analyst AK Prabhakar has maintained 'hold' rating on Glenmark Pharmaceutical Limited stock with long-term targets of Rs 450 and 475.

Today, the stock of the company opened at Rs 364.70 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 382 and a low of Rs 220 on BSE.

Current EPS & P/E ratio stood at 17.18 and 20.37 respectively.

Glenmark Pharmaceuticals has finished the third phase of human experimentations of Crofelemer, a novel drug to cure HIV-related diarrhea, which could make more than $80 million.

Syndicate content